Stock Financial Ratios


MTNB / Matinas Biopharma Holdings, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price1.17
Volume77,700.00
Market Cap ($M)104.44
Enterprise Value ($M)89.51
Book Value ($M)7.15
Book Value / Share0.12
Price / Book6.63
NCAV ($M)8.37
NCAV / Share0.15
Price / NCAV6.46
Income Statement (mra) ($M)
Revenue0.00
EBITDA-8.26
Net Income-7.60
Balance Sheet (mrq) ($M)
Cash & Equivalents11.27
Cash / Share0.20
Assets17.80
Liabilities2.47
Quick Ratio3.16
Current Ratio3.16
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-1.06
Return on Assets (ROA)-0.43
Return on Equity (ROE)-1.06
Identifiers and Descriptors
CUSIP576810105
Central Index Key (CIK)1582554
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Share Statistics
Common Shares Outstanding (M)91.97
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Finished Goods Per Share0.00
Liabilities Other Non Current Per Share0.00
Property Plant And Equipment Gross Per Share0.02
Intangibles Per Share0.00
Property Plant And Equipment Per Share0.02
Accumulated Depreciation And Depletion Per Share0.00
Additional Paid In Capital Per Share0.92
Cash And Equivalents Per Share0.20
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Accounts Receivable Per Share0.00
Equity Per Share0.26
Inventory Raw Materials Per Share0.00
Retained Earnings Per Share0.76
Long Term Debt Per Share0.00
Assets Current Per Share0.20
Treasury Stock Per Share0.00
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Goodwill Per Share0.02
Inventory Per Share0.00
Liabilities Per Share0.04
Property Plant And Equipment Net Per Share0.02
Liabilities And Stock Equity Per Share0.31
Liabilities Current Per Share0.02
Cash Per Share0.20
Assets Other Non Current Per Share0.00
Deferred Income Tax Liabilities Per Share0.02
Inventory Work In Progress Per Share0.00
Assets Per Share0.31
Debt Per Share0.00

Related News Stories

BRIEF-Matinas BioPharma says qtrly loss per share $0.04‍​

2017-11-15 reuters
* Matinas BioPharma Holdings Inc - qtrly loss per share $0.04‍​ Source text for Eikon: Further company coverage: (10-0)

3 Companies Spearheading the Antibiotics Space in 2018

2017-11-10 247wallst
This may turn out to be a pivotal year in antibiotic development, after decades of dramatic decline in the space. While 1980 to 1984 saw 18 new antibiotic approvals, the period from 2005 and 2012 saw only four. As resistance becomes a more and more pressing issue, now even threatening to make routine surgery very difficult due to infection concerns, the need for new antibiotics is becoming very urgent. (64-0)

Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today

2017-06-26 fool
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

CUSIP: 576810105